Hence, it is likely that the differential expression of IL-24 receptor and/or IL-24 by specific B cell subsets during B cell activation (early post-measles vaccine), physiologically “fine-tunes” the balance between plasma cell and MBC commitment, thus affecting antigen-specific plasmablast/plasma cell response and antibody production. The gene discussed is IL24; the disease is measles.